There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inovio Pharmaceuticals (INO), Insmed (INSM) and Momenta Pharma (MNTA) with bullish sentiments.
Inovio Pharmaceuticals (INO)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Inovio Pharmaceuticals, with a price target of $13.00. The company’s shares closed last Monday at $3.91.
According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 14.0% and a 48.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Turning Point Therapeutics, and Biospecifics Technologies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Inovio Pharmaceuticals with a $9.43 average price target, representing an 116.3% upside. In a report issued on January 23, Maxim Group also reiterated a Buy rating on the stock with a price target.
See today’s analyst top recommended stocks >>
Insmed (INSM)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Insmed, with a price target of $52.00. The company’s shares closed last Monday at $28.88.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 12.2% and a 48.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Insmed with a $50.00 average price target, representing a 66.2% upside. In a report released yesterday, Cowen & Co. also maintained a Buy rating on the stock with a $56.00 price target.
Momenta Pharma (MNTA)
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Momenta Pharma, with a price target of $36.00. The company’s shares closed last Monday at $29.39, close to its 52-week high of $31.90.
According to TipRanks.com, Tsao is a 4-star analyst with an average return of 8.7% and a 52.5% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Protagonist Therapeutics, and Minerva Neurosciences.
Currently, the analyst consensus on Momenta Pharma is a Strong Buy with an average price target of $38.20, a 30.3% upside from current levels. In a report issued on January 27, Stifel Nicolaus also reiterated a Buy rating on the stock with a $43.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
